Where health tech meets real change

Market access strategy, pricing logic, and reimbursement positioning have moved from the back office to the boardroom. Whether you’re a seed-stage health tech defining your first evidence roadmap or a late-stage company preparing for partnership or exit, how you think about reimbursement pathways, value-based pricing, and payer narratives is no longer a regulatory checkbox – it’s a core determinant of company valuation, scalability, and investor confidence.

This workshop brings together founders, business development leaders, and market access professionals to explore a fundamental shift in how pricing and reimbursement should be aligned with how investors evaluate ventures. Early reimbursement thinking, evidence strategy, and pricing logic are now read as signals of commercial maturity and risk management – long before a product reaches its first payer negotiation.

Equally, a credible pricing strategy – one that aligns clinical evidence, health economic models, and willingness-to-pay across payer segments – is increasingly scrutinised in due diligence and partnership discussions.

We’ll examine how reimbursement architecture, pricing narrative, and market access strategy collectively shape commercialisation and funding decisions, influence partnership terms, and define exit potential – and what it takes to speak this language fluently at every stage of your company’s growth.

Who it’s for
Founders, BD leaders, and market access professionals in health tech and MedTech companies – from seed stage to late stage.